Physician profile
Samir Ahuja
NPI 1497850622
$429,862.35
in general payments reported to CMS, 2019-2025
26 companies · $1,906 in 2025
The $1,906 reported for 2025 was more than what 94% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138K · 2020: $65K · 2021: $137K · 2022: $57K · 2023: $28K · 2024: $2,355 · 2025: $1,906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Travel and Lodging: $6,375 · Consulting Fee: $4,930 · Food and Beverage: $2,554.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,450.00 |
| Travel and Lodging | $6,375.47 |
| Consulting Fee | $4,930.00 |
| Food and Beverage | $2,553.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $313,064.62 | 2019-2023 | Orilissa, Lo Loestrin Fe |
| Myovant Sciences INC. | $61,223.46 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $25,868.49 | 2023-2025 | Myfembree, Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $22,771.61 | 2019-2025 | |
| Pfizer INC. | $5,054.97 | 2019-2025 | |
| Astellas Pharma US INC | $419.28 | 2019-2025 | Veozah, Myrbetriq |
| Therapeuticsmd, INC. | $207.57 | 2019-2022 | |
| Exeltis, USA INC. | $187.13 | 2022-2025 | Slynd |
| Optumhealth Care Solutions, LLC | $170.83 | 2023-2025 | Vivify Health Care Team Portal 001, Eitan Medical, Vivify Health Care Team Portal |
| Millicent US INC | $154.56 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Mayne Pharma Commercial LLC | $127.22 | 2021-2023 | |
| Shield Therapeutics INC | $104.74 | 2022-2024 | |
| Gynesonics, INC. | $81.20 | 2022 | |
| Axonics, INC. | $78.12 | 2023-2024 | Axonics, Bulkamid |
| Amag Pharmaceuticals, INC. | $66.40 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aspira Women'S Health INC | $61.78 | 2022 | |
| Lupin INC. | $43.15 | 2020-2021 | |
| Evofem Biosciences, INC. | $31.19 | 2021 | |
| Meditrina | $26.56 | 2021-2025 | |
| Coopersurgical, INC. | $25.46 | 2019-2021 | |
| Duchesnay USA Incorporated | $23.87 | 2019 | |
| Novo Nordisk INC | $16.00 | 2019 | |
| Allergan, INC. | $14.32 | 2019 | |
| Roche Diagnostics Corporation | $13.86 | 2019 | |
| Minerva Surgical, INC | $13.13 | 2019 | |
| Avion Pharmaceuticals | $12.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samir Ahuja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.